Author Archives: Jennifer Ringler
By Jennifer Ringler | Published: December 5, 2011
The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
By Jennifer Ringler | Published: November 1, 2011
A new coalition for sharing pharma IP takes aim at the increasing burden of neglected tropical diseases in the developing world. According to the World Health Organization, neglected tropical diseases affect more than one billion of the world’s poorest 2.7 billion people. Many of these diseases, which can cause blindness and other debilitating symptoms, have reached [...]
By Jennifer Ringler | Published: October 4, 2011
The winners of the fifth annual Prix Galien USA represent the progress of the entire industry and show us how far we’ve come in advancing the pace of innovation and commercializing new medicines that save lives and improve standard of care. Pharmaceutical Executive served as a lead media partner for the 2011 Prix Galien awards, held [...]
By Jennifer Ringler | Published: September 19, 2011
Pharmaceutical Executive recently spoke with David Vance, Senior Director of the Compliance Counsel at Noven Pharmaceuticals, about the birth of Expanded Access Programs and the role patient advocacy groups can play in shaping those programs.
By Jennifer Ringler | Published: July 19, 2011
Steven Blum, Director of Health Economics at Forest Laboratories and one of Pharm Exec’s 2011 Emerging Pharma leaders, recently spoke with Associate Editor Jennifer Ringler on building leadership and team rapport in today’s lean organization.